NeuroQuant clearance automates amyloid quantification for Alzheimer’s imaging, trading radiologist’s judgment call for standardized number.
Reading a brain scan for Alzheimer’s has long come down to a radiologist’s trained eye and best guess. That guesswork just got a software co-pilot with the FDA’s sign-off attached.
Cortechs.ai announced on 18 August that its NeuroQuant PET platform received 510(k) clearance from the FDA, the pathway used when a device is shown to work as well as one already on the market. The clearance, numbered K261916, covers the software’s use in reading positron emission tomography, or PET, scans for cognitive impairment and related neurological conditions [1].
Amyloid PET scans work by injecting a radioactive tracer that binds to amyloid, the protein that clumps into the plaques found in Alzheimer’s patients’ brains. A radiologist looks at the resulting image and judges how much amyloid is present. That judgment varies – from one reader to another, one hospital’s scanner to another’s.
NeuroQuant PET is built to strip out some of that variability. It automatically maps different brain regions and calculates standardized uptake value ratios, essentially how much tracer built up where, then converts the result into a unit called Centiloids. These units are designed specifically to let scans be compared apples-to-apples no matter which tracer or scanner produced them. The software covers three of the most widely used amyloid tracers, (flutemetamol, florbetaben and florbetapir), and plugs into existing PET-CT, PET-MR and PET-only setups.
Why a number beats an impression
“Automated quantitative PET imaging represents the next frontier in precision and personalized medicine for Alzheimer’s disease and related neurocognitive disorders,” said Dr Ana Franceschi. “These new technological advancements are enabling the shift from phenotype-based assessment to a biological, biomarker-driven approach in assessing neurodegenerative disease. I am excited about the role NeuroQuant PET will play in shaping the future of how these conditions are understood and managed.”
The shift from “this scan looks concerning” to “here is the number, and here is what it means” isn’t just tidier record-keeping. Newer Alzheimer’s treatments increasingly require confirming amyloid presence before a patient can even start therapy. A standardized, automated readout stops being a nice-to-have and starts being closer to a prerequisite for getting the right patients matched to the right drug on time.
“NeuroQuant PET reflects our commitment to advancing quantitative imaging in dementia care, giving clinicians objective, reproducible measurements they can trust, so patients get earlier answers and more confident treatment decisions,” said Kyle Frye, CEO of Cortechs.ai. “With FDA 510(k)-clearance status, we look forward to expanding access to standardized PET quantification that supports precision medicine in Alzheimer’s disease and related dementias.”
One product in a growing portfolio
Cortechs.ai isn’t new to this territory. The company already sells imaging software used across epilepsy, multiple sclerosis and brain trauma, alongside tools for prostate cancer assessment. NeuroQuant PET extends the same standardized, automated approach into a diagnostic category that matters more each year, as amyloid-targeting Alzheimer’s drugs move further into mainstream practice and require exactly this kind of confirmation before treatment can begin.
Software clearances rarely feel like breakthroughs; there’s no dramatic before-and-after, no patient story attached to a 510(k) number. But earlier, more consistent detection of amyloid buildup is the unglamorous infrastructure longevity medicine actually runs on. Alzheimer’s treatments only work if they start early enough, and starting early means knowing, with real confidence, what’s happening inside the brain well before symptoms are undeniable.
NeuroQuant PET doesn’t add years to anyone’s life by itself. It narrows the gap between when the disease begins and when doctors can actually see it, and in neurodegeneration, that gap is often the difference between catching a treatable window and missing it entirely.
